Current News

Contact | Print version | PDF version | Send article | RSS feed

DxS receives Biotechnology Award for Cancer product from BioNow

30 Nov 2006 - DxS has won a 'Biotechnology Project of the Year' award for its highly sensitive EGFR (Epidermal Growth Factor Receptor) Mutation Test Kit. Sponsored by the Manchester based law firm Pannone LLP, the award was presented by Bionow, the Northwest Regional Development Agency's (NWDA) biotechnology cluster support group, at the agency's annual awards ceremony in Cheshire, UK.
 
According to the company, recent advances in the field of cancer drugs have provided DxS with an opportunity to develop the world's first tumour mutation analysis kit to identify patients who will respond well to certain lung cancer therapies. This new oncogene assay can detect the 29 most common somatic mutations in the Epidermal Growth Factor Receptor Gene, identifying mutations that are not visible by sequencing techniques.